The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC.
A. Vashishtha
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
P. H. Patel
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
W. Yu
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
J. G. Bothos
Employment or Leadership Position - Genentech
Stock Ownership - Genentech (B)
J. Simpson
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
T. Maneatis
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
L. Doessegger
Employment or Leadership Position - Roche
A. C. Peterson
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
C. Clement-Duchene
No relevant relationships to disclose
G. Robinet
Honoraria - Roche
M. Krzakowski
No relevant relationships to disclose
G. R. Blumenschein
Research Funding - Genentech
J. H. Goldschmidt
No relevant relationships to disclose
D. B. Daniel
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Genentech (U)